NEWS

Earlier this month, EORTC were thrilled to announce that Jordan has officially joined the OligoRARE study with the activation of King Hussein Cancer Foundation and Centre.

This marks the first trial initiated under the EORTC Middle East Coordination Office (MECO) agreement, with further sites in the region to follow.

This expansion increases access to a clinical study exploring whether adding a precise form of radiotherapy (SBRT) to standard treatment can help patients with rare cancers that have spread to a few areas, live longer. We gratefully acknowledge the dedication of the KHCC team and the leadership of Dr Asem Mansour, MD and Amal Al Omari in making this milestone possible.

You can also help support EORTC’s game-changing clinical research to unleash scientific breakthrough and transform cancer patients’ lives. Learn how to GET INVOLVED, or Make a Contribution Now.